Endocrinology

The Phase 3 SURPASS-PEDS trial found tirzepatide improved glycemic control and weight outcomes in youth-onset type 2 diabetes, with benefits lasting one year.

Michael Haller, MD, discusses inhaled insulin’s safety, off-label use, and future role in easing type 1 diabetes management for children.

Richard Auchus, MD, PhD, discusses how crinecerfont is improving CAH care and easing the transition from pediatric to adult management.

Manufacturer MannKind has submitted a supplemental Biologics Application to the FDA for its inhaled insulin Afrezza.

The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.

The combination therapy yielded boosted treatment benefits of navepegritide, including improvement in mean ACH Z-score and mean annualized growth.

With the new drug application accepted with priority review, the FDA has assigned a date of November 30, 2025, to complete its review for potential approval.

The decision makes hydrocortisone oral solution (Khindivi; Eton Pharmaceuticals) the only FDA-approved oral formulation of hydrocortisone.

Somapacitan was non-inferior and had a similar safety profile and clinical outcomes compared to once-daily somatropin in improving yearly growth rates.

Most want to start the conversation, but confidence and timing vary.

The FDA is warning diabetes patients that information from CGMs, insulin pumps, and automated dosing systems could fail to be delivered if smartphone settings are not properly configured.

Greg Forlenza, MD, highlights data from the CLVer trial that included advanced diabetes technology in newly diagnosed T1D patients.

The primary endpoint was non-inferiority in HbA1c levels after 26 weeks.

Greg Forlenza, MD, offers practical advise for primary care providers regarding continuous glucose monitors and automatic insulin delivery systems.

A discussion of the evolving landscape of diabetes technology and its implications for primary care providers.

In this video interview, Herbert Bravo, MD, explains how implementing autoimmune diabetes screenings in the primary care setting can benefit the child several ways.

A further understanding of the role SARS-CoV-2 plays in T2D incidence can add an important component to benefit and risk considerations to prevent COVID-19.

Look back at several quick video interviews discussing the expanding role of artificial intelligence, how RSV treatment has evolved, and much more.

Brittany Bruggeman, MD, emphasizes that many patients with type 1 diabetes are unaware of the availability of advanced technologies like CGMs and automated insulin delivery systems.

Brittany Bruggeman, MD, highlighted the ability to predict type 1 diabetes months to years in advance through islet autoantibodies, and how the pediatrician can play a role.

This decision marks the second time the FDA has issued a complete response letter (CRL) for dasiglucagon to treat hypoglycemia in patients 7 days and up with congenital hyperinsulinism.

Andrew Dauber, MD, MMSc, of Children's National Hospital joined us to discuss potential advantages of LUM-201 as it goes through the clinical pipeline.

Linda DiMeglio, MD, MPH, joined us to discuss the “Consensus Guidance for Monitoring Persons with Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes."

Andrew Dauber, MD, MMSc, of Children's National Hospital joined us to talk PGHD and the role of the pediatrician when it comes to treatment.

The USPSTF statement aligns with the 2015 recommendation on insufficient evidence for pregnancy iron deficiency screening or supplementation.